作为一家曾经在新华社、人民日报、中央电视台、华尔街日报、纽约时报等多个知名媒体担任资深新闻记者和编辑的全球新闻人物，我今天很荣幸地向您宣布，总部位于巴黎的生物技术公司 Aqemia 已经使用人工智能技术成功获得了 3000 万欧元的 A 轮追加融资。
此次融资由名为 Wendel Growth 的投资公司领导，同时也有法国 VC Eurazeo 和公共银行 Bpifrance、Elaia 等机构参与。值得注意的是，Aqemia 开发的这种人工智能驱动的技术，据称可以大大加速分子的发现和设计，这些分子有可能成为对抗不同疾病的药物。
这场融资的数额是 Aqemia 全股权融资总额达到 6000 万欧元的重要里程碑。Aqemia 的这一突破性技术，不仅仅为药物研发领域带来了全新的可能性，也让我们看到了人工智能技术的巨大潜力。
此消息来源于 Sifted 媒体，详细报道了 Aqemia 的发展动态。
英语如下：
News Title: Aqemia, a biotechnology company using artificial intelligence to accelerate drug discovery, raises 3 million euros in Series A follow-on financing
Keywords: Aqemia, funding, new technology
News Content: Global News – Aqemia, an innovative biotechnology company, recently announced that it has successfully raised 3 million euros in Series A follow-on financing, led by investment firm Wendel Growth, with participation from French VC Eurazeo and public banks Bpifrance, Elaia. Notably, Aqemia’s artificial intelligence-driven technology, which is said to be able to greatly accelerate the discovery and design of molecules that could potentially become drugs against different diseases, has been successfully funded.
This round of financing marks an important milestone in Aqemia’s full equity financing amount of 6 million euros. Aqemia’s groundbreaking technology not only brings new possibilities to the drug research and development field but also demonstrates the immense potential of artificial intelligence.
This news comes from Sorted Out, which provides detailed coverage of Aqemia’s developments.
【来源】https://sifted.eu/articles/aqemia-60m-series-a
Views: 2